Cargando…
Antiphospholipidantikörpersyndrom
□ BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies mainly characterized by the presence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACA). □ CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the appearance of frequent thromboses,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Urban & Vogel
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095803/ https://www.ncbi.nlm.nih.gov/pubmed/10194954 http://dx.doi.org/10.1007/BF03044707 |
_version_ | 1783510688972406784 |
---|---|
author | Schmidt, Rüdiger Scheuermann, Ernst-Heinrich Viertel, Achim Geiger, Helmut Scharrer, Inge |
author_facet | Schmidt, Rüdiger Scheuermann, Ernst-Heinrich Viertel, Achim Geiger, Helmut Scharrer, Inge |
author_sort | Schmidt, Rüdiger |
collection | PubMed |
description | □ BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies mainly characterized by the presence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACA). □ CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the appearance of frequent thromboses, repeated fetal losses and thrombocytopenia. Other clinical manifestations associated with APA include migraine, chorea, hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic antiphospholipid syndrome. LA and ACA occur in a variety of clinical conditions (secondary antiphospholipid antibody syndrome, SAPS), including other autoimmune disorders, infectious diseases, neoplastic disorders, in association with the use of certain drugs or in otherwise healthy individuals (primary antiphospholipid antibody syndrome, PAPS). □ TREATMENT: Patients with thrombosis associated with APA should receive long-term anticoagulation therapy, whereas treatment of asymptomatic patients seems to be not indicated, because only approximately 10% of patients with APA may develop thrombotic complications. In patients with PAPS there is no evidence that the prophylactic administration of immunosuppressive drugs will prevent thromboembolic events. |
format | Online Article Text |
id | pubmed-7095803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Urban & Vogel |
record_format | MEDLINE/PubMed |
spelling | pubmed-70958032020-03-26 Antiphospholipidantikörpersyndrom Schmidt, Rüdiger Scheuermann, Ernst-Heinrich Viertel, Achim Geiger, Helmut Scharrer, Inge Med Klin (Munich) Übersicht □ BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies mainly characterized by the presence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACA). □ CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the appearance of frequent thromboses, repeated fetal losses and thrombocytopenia. Other clinical manifestations associated with APA include migraine, chorea, hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic antiphospholipid syndrome. LA and ACA occur in a variety of clinical conditions (secondary antiphospholipid antibody syndrome, SAPS), including other autoimmune disorders, infectious diseases, neoplastic disorders, in association with the use of certain drugs or in otherwise healthy individuals (primary antiphospholipid antibody syndrome, PAPS). □ TREATMENT: Patients with thrombosis associated with APA should receive long-term anticoagulation therapy, whereas treatment of asymptomatic patients seems to be not indicated, because only approximately 10% of patients with APA may develop thrombotic complications. In patients with PAPS there is no evidence that the prophylactic administration of immunosuppressive drugs will prevent thromboembolic events. Urban & Vogel 1999 /pmc/articles/PMC7095803/ /pubmed/10194954 http://dx.doi.org/10.1007/BF03044707 Text en © Urban & Vogel 1999 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Übersicht Schmidt, Rüdiger Scheuermann, Ernst-Heinrich Viertel, Achim Geiger, Helmut Scharrer, Inge Antiphospholipidantikörpersyndrom |
title | Antiphospholipidantikörpersyndrom |
title_full | Antiphospholipidantikörpersyndrom |
title_fullStr | Antiphospholipidantikörpersyndrom |
title_full_unstemmed | Antiphospholipidantikörpersyndrom |
title_short | Antiphospholipidantikörpersyndrom |
title_sort | antiphospholipidantikörpersyndrom |
topic | Übersicht |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095803/ https://www.ncbi.nlm.nih.gov/pubmed/10194954 http://dx.doi.org/10.1007/BF03044707 |
work_keys_str_mv | AT schmidtrudiger antiphospholipidantikorpersyndrom AT scheuermannernstheinrich antiphospholipidantikorpersyndrom AT viertelachim antiphospholipidantikorpersyndrom AT geigerhelmut antiphospholipidantikorpersyndrom AT scharreringe antiphospholipidantikorpersyndrom |